<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02965248</url>
  </required_header>
  <id_info>
    <org_study_id>1608163-15</org_study_id>
    <nct_id>NCT02965248</nct_id>
  </id_info>
  <brief_title>Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study)</brief_title>
  <official_title>Multicenter, Randomized Controlled Trial Designed to Evaluate the Efficacy and Safety of Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Raltitrexed or Oxaliplatin Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy and safety of adjuvant hyperthermic
      intraperitoneal chemotherapy (HIPEC) with raltitrexed or oxaliplatin versus no HIPEC in
      locally advanced colorectal cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peritoneum is one of the common sites of metastasis in advanced stage colorectal cancer
      patients, resulting in a poor prognosis. Hyperthermic intraperitoneal chemotherapy (HIPEC) is
      effective to colorectal peritoneal metastasis and may play a significant role in reducing the
      risk of metachronous peritoneal metastasis among patients with locally advanced colorectal
      cancer. Oxaliplatin is routinely used for HIPEC in the Europe and Raltitrexed may be another
      ideal drug for HIPEC. The present phase II multicenter, randomized controlled trial is
      designed to evaluate the efficacy and safety of adjuvant HIPEC with raltitrexed or
      oxaliplatin versus no HIPEC in locally advanced colorectal cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>peritoneal metastasis rate</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>liver metastasis rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life questionnaire</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity by NCI CTCAE v.4.0</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">147</enrollment>
  <condition>Locally Advanced Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo radical resection of colorectal cancer (open/laparoscopic) and receive standard adjuvant systemic chemotherapy comprising mFOLFOX6/CapeOx/sLV5FU2/Cape. Systemic chemotherapy will continue for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo radical resection of colorectal cancer (open/laparoscopic) and receive standard adjuvant systemic chemotherapy comprising mFOLFOX6/CapeOx/sLV5FU2/Cape. Systemic chemotherapy will continue for 6 months. Patients also undergo HIPEC with raltitrexed (3mg/m2) intraperitoneally for 60 minutes during surgery or within 10 days after the operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo radical resection of colorectal cancer (open/laparoscopic) and receive standard adjuvant systemic chemotherapy comprising mFOLFOX6/CapeOx/sLV5FU2/Cape. Systemic chemotherapy will continue for 6 months. Patients also undergo HIPEC comprising oxaliplatin (130mg/m2) intraperitoneally during surgery and hyperthermia for 30 minutes, following leucovorin calcium (20mg/m2 intravenously) and 5-FU (400 mg/m2 intravenously)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard adjuvant systemic chemotherapy</intervention_name>
    <description>Patients undergo radical surgery with standard adjuvant systemic chemotherapy (mFOLFOX6/CapeOx/sLV5FU2/Cape).
mFOLFOX6: oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.
CapeOx: oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.
sLV5FU2: leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.
Cape: capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <other_name>adjuvant oxaliplatin, 5-FU, and leucovorin calcium (mFOLFOX6)</other_name>
    <other_name>adjuvant oxaliplatin and capecitabine (CapeOx)</other_name>
    <other_name>adjuvant 5-FU and leucovorin calcium (sLV5FU2)</other_name>
    <other_name>adjuvant capecitabine (Cape)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hyperthermic intraperitoneal chemotherapy (HIPEC) with raltitrexed</intervention_name>
    <description>Raltitrexed (3 mg/m2) is added to the perfusate after attaining 42 degrees of inflow temperature and last for 60 minutes.</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Intraperitoneal raltitrexed 3 mg/m2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin</intervention_name>
    <description>Before the beginning of HIPEC, 5-FU 400 mg/m2 and leucovorin calcium 20 mg/m2 will be administered intravenously to potentiate oxaliplatin activity. Oxaliplatin (130 mg/m2) is added to the perfusate after attaining 42 degrees inflow temperature with a total of 30 minutes perfusion time.</description>
    <arm_group_label>Arm C</arm_group_label>
    <other_name>I.V. leucovorin calcium 20 mg/m2</other_name>
    <other_name>I.V. 5-FU 400 mg/m2</other_name>
    <other_name>Intraperitoneal oxaliplatin 130 mg/m2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Joined the study voluntarily and signed informed consent form

          -  Eastern Cooperative Oncology Group performance status of 0 to 1

          -  Life expectancy of more than 5 years

          -  Colorectal adenocarcinoma / mucinous adenocarcinoma / signet ring cell cancer
             confirmed by histopathology

          -  Stage T4NanyM0 cancer; or stage T3NanyM0 mucinous adenocarcinoma / signet ring cell
             cancer / adenocarcinoma with partly mucinous adenocarcinoma or signet ring cell cancer

          -  R0 resection of colorectal cancer

          -  Neutrophils (ANC) ≥ 1.5×10^9/L, Platelet count (Pt) ≥ 100× 10^9/L, Hemoglobin (Hb) ≥
             80 g/L, Hepatic function: ALT and AST ≤ 2.5 times upper limit of normal (ULN) and TBIL
             ≤ 1.5 times ULN, Renal function: creatinine ≤ 1.5 times ULN

          -  Use of an effective contraceptive for adults to prevent pregnancy

        Exclusion Criteria:

          -  Rectal cancer below peritoneal reflection (≤ 8cm above the anal verge)

          -  Other malignant tumors within the past 5 years, except for skin basal cell carcinoma,
             or cervical carcinoma in situ, who survived from radical treatment

          -  Severe adhesion of peritoneal cavity impossible to separate

          -  Abdominal infection

          -  Allergic to raltitrexed, 5-FU, and oxaliplatin; Dihydropyrimidine dehydrogenase (DPD)
             enzyme deficiency

          -  Uncontrolled seizures or psychiatric diseases, loss of control over their own behavior

          -  Drug addiction, Alcoholism or AIDS

          -  Impossible to tolerate the operation due to severe cardiac, lung, and vascular
             diseases

          -  Pregnant or breast-feeding women or people during the birth-period who refused to take
             contraceptives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guoxiang Cai, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guoxiang Cai, M.D. Ph.D.</last_name>
      <phone>+86 13611831623</phone>
      <email>gxcai@fudan.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2016</study_first_submitted>
  <study_first_submitted_qc>November 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2016</study_first_posted>
  <last_update_submitted>November 11, 2016</last_update_submitted>
  <last_update_submitted_qc>November 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Guoxiang Cai</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Locally advanced colorectal cancer</keyword>
  <keyword>Hyperthermic intraperitoneal chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Raltitrexed</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

